Less physical activity Maintaining or increasing exercise is important for ongoing weight management
Immune System Support: Crucial for maintaining a robust and healthy immune response
During the following 26 weeks of treatment (extension phase), discontinuations as a result of adverse events occurred in 2.4% of patients in the T-T group (patients treated with tesamorelin for Week 0-26 and with tesamorelin for Week 26-52) and 5.2% of patients in the T-P group (patients treated with tesamorelin for Week 0-26 and with placebo for Week 26-52)
Whilst flatulence isnt always prominently listed in official prescribing information, it has been frequently reported by people using semaglutide (Wegovy) or tirzepatide (Mounjaro)particularly during the initial weeks of treatment
Semaglutide (Wegovy/Ozempic): The GLP-1 PathwaySemaglutide is classified as a glucagon-like peptide-1 (GLP-1) receptor agonist.2 It works by mimicking the action of a natural hormone called GLP-1, which is released by the gut in response to eating.1 By activating GLP-1 receptors in various parts of the body, semaglutide exerts several effects relevant to weight management and blood sugar control: Enhances Insulin Secretion: It prompts the pancreas to release more insulin, primarily when blood sugar levels are elevated after a meal
tirzepatide side effects often diminish as your body adjusts during dose escalation